Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation

NCT07650357 is registered in ClinicalTrials.gov with Clasp Therapeutics, Inc. as lead sponsor.

NCT NCT07650357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07650357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation
Lead sponsor
Clasp Therapeutics, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2029
Enrollment
140 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colorectal cancer, non small cell lung cancer, pancreatic carcinoma